Geneva, Switzerland and Boston, MA – 07 August, 2017 – ObsEva SA (NASDAQ: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics…
Tag: 2017
ObsEva Announces Presentations Related to its Assisted Reproductive Technology (ART) and Pre-term labor (PTL) Development Programs at ESHRE 2017 Annual Meeting
Phase 2 nolasiban previously reported data supports potential for meaningfully increasing live birth rates in ART Non-clinical results of OBE022…
Q2 2017 ObsEva SA Earnings Conference call
ObsEva to report financial results for the second quarter on Tuesday, August 15, 2017 Date & Time: 15 August 2017 at…
ObsEva Annual General Meeting 2017
Tuesday, June 13, 2017 Location: Geneva Supporting Materials:
ObsEva Annual General Meeting
Supporting Materials Invitation to the Annual General Meeting of Shareholders ObsEva 2017 Equity Incentive Plan Annual Report Date & Time: Tuesday,…
ObsEva SA at the Jefferies Healthcare Conference
Supporting Materials Jefferies Healthcare Conference Date & Time: Thursday, June 8, 2017 at 8:30 a.m. ET
ObsEva SA Announces the Completion of a Phase 1 PK/PD Clinical Trial Evaluating Different Doses of OBE2109 and Add-Back Therapy
– OBE2109 is a GnRH receptor antagonist currently in development as both a stand-alone treatment and with add-back therapy designed…
ObsEva SA to Attend Jefferies Healthcare Conference in NYC
Geneva, Switzerland and Boston, MA – 31 May 2017 – ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics…